 Patients will enter the Screening Period once the informed consent and photographic consent process has been completed. Patients with mild-to-moderate plaque psoriasis, as defined by a Psoriasis Area and Severity Index PASI score between 2 and 12, appropriate for topical treatment that covers a minimum of 1.0 and a maximum of 10 BSA, in the permitted treatment areas, and who meet all of the inclusion and none of the exclusion criteria will be enrolled. 